These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 11109013)

  • 21. Designing fluoroquinolone breakpoints for Streptococcus pneumoniae by using genetics instead of pharmacokinetics-pharmacodynamics.
    Smith HJ; Noreddin AM; Siemens CG; Schurek KN; Greisman J; Hoban CJ; Hoban DJ; Zhanel GG
    Antimicrob Agents Chemother; 2004 Sep; 48(9):3630-5. PubMed ID: 15328145
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmacodynamic modeling of carbapenems and fluoroquinolones against bacteria that produce extended-spectrum beta-lactamases.
    Moczygemba LR; Frei CR; Burgess DS
    Clin Ther; 2004 Nov; 26(11):1800-7. PubMed ID: 15639692
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparative in-vitro efficacy of fluoroquinolones against Streptococcus pneumoniae recovered from bacterial keratitis as determined by E-test.
    Ramakrishnan R; Ramesh S; Bharathi MJ; Amuthan M; Viswanathan S
    Indian J Pathol Microbiol; 2010; 53(2):276-80. PubMed ID: 20551532
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacodynamic evaluation of tosufloxacin against Streptococcus pneumoniae in an in vitro model simulating serum concentration.
    Fukuda Y; Takahata M; Mitsuyama J
    J Infect Chemother; 2006 Feb; 12(1):1-8. PubMed ID: 16506083
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Can antimicrobial susceptibility testing results for ciprofloxacin or levofloxacin predict susceptibility to a newer fluoroquinolone, gatifloxacin?: Report from The SENTRY Antimicrobial Surveillance Program (1997-99).
    Jones RN; Pfaller MA;
    Diagn Microbiol Infect Dis; 2001 Apr; 39(4):237-43. PubMed ID: 11404067
    [TBL] [Abstract][Full Text] [Related]  

  • 26. In vitro characterization of fluoroquinolone concentration/MIC antimicrobial activity and resistance while simulating clinical pharmacokinetics of levofloxacin, ofloxacin, or ciprofloxacin against Streptococcus pneumoniae.
    Madaras-Kelly KJ; Demasters TA
    Diagn Microbiol Infect Dis; 2000 Aug; 37(4):253-60. PubMed ID: 10974576
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacodynamics of levofloxacin and ofloxacin against Streptococcus pneumoniae.
    Bauernfeind A
    J Antimicrob Chemother; 1999 Jun; 43 Suppl C():77-82. PubMed ID: 10404343
    [TBL] [Abstract][Full Text] [Related]  

  • 28. In vitro activity of fluoroquinolones (gatifloxacin, levofloxacin and trovafloxacin) and seven other antibiotics against Streptococcus pneumoniae.
    Nicodemo AC; Mendes CM; Oplustil CP; Sinto S
    Braz J Infect Dis; 2001 Apr; 5(2):50-2. PubMed ID: 11493408
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmacodynamics of the new fluoroquinolone gatifloxacin in murine thigh and lung infection models.
    Andes D; Craig WA
    Antimicrob Agents Chemother; 2002 Jun; 46(6):1665-70. PubMed ID: 12019073
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Simulated comparison of the pharmacodynamics of ciprofloxacin and levofloxacin against Pseudomonas aeruginosa using pharmacokinetic data from healthy volunteers and 2002 minimum inhibitory concentration data.
    Burgess DS; Hall RG
    Clin Ther; 2007 Jul; 29(7):1421-7. PubMed ID: 17825693
    [TBL] [Abstract][Full Text] [Related]  

  • 31. AUC/MIC relationships to different endpoints of the antimicrobial effect: multiple-dose in vitro simulations with moxifloxacin and levofloxacin.
    Firsov AA; Zinner SH; Vostrov SN; Portnoy YA; Lubenko IY
    J Antimicrob Chemother; 2002 Oct; 50(4):533-9. PubMed ID: 12356798
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pharmacodynamic assessment of gatifloxacin against Streptococcus pneumoniae.
    Mattoes HM; Banevicius M; Li D; Turley C; Xuan D; Nightingale CH; Nicolau DP
    Antimicrob Agents Chemother; 2001 Jul; 45(7):2092-7. PubMed ID: 11408228
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical implications of pharmacokinetics and pharmacodynamics of fluoroquinolones.
    Wispelwey B
    Clin Infect Dis; 2005 Jul; 41 Suppl 2():S127-35. PubMed ID: 15942879
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparative in vitro activity and pharmacodynamics of five fluoroquinolones against clinical isolates of Streptococcus pneumoniae.
    Kays MB; Conklin M
    Pharmacotherapy; 2000 Nov; 20(11):1310-7. PubMed ID: 11079279
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Resistance of Streptococcus pneumoniae to fluoroquinolones--United States, 1995-1999.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2001 Sep; 50(37):800-4. PubMed ID: 11785571
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparative activity of gatifloxacin and other antibiotics against 4009 clinical isolates of Streptococcus pneumoniae in the United States during 1999-2000.
    White RL; Enzweiler KA; Friedrich LV; Wagner D; Hoban D; Bosso JA
    Diagn Microbiol Infect Dis; 2002 Jul; 43(3):207-17. PubMed ID: 12106954
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Evaluation by Monte Carlo simulation of levofloxacin dosing for complicated urinary tract infections caused by Escherichia coli or Pseudomonas aeruginosa.
    Deguchi T; Seike K; Yasuda M; Matsumoto T
    J Infect Chemother; 2011 Oct; 17(5):726-30. PubMed ID: 21409530
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Microbiologic effectiveness of time- or concentration-based dosing strategies in Streptococcus pneumoniae.
    Ibrahim KH; Hovde LB; Ross G; Gunderson B; Wright DH; Rotschafer JC
    Diagn Microbiol Infect Dis; 2002 Nov; 44(3):265-71. PubMed ID: 12493174
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Broth microdilution and E-test for determining fluoroquinolone activity against Streptococcus pneumoniae.
    Kays MB; Graff MA
    Ann Pharmacother; 2002 Mar; 36(3):416-22. PubMed ID: 11895052
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparative pharmacodynamics of the new fluoroquinolone ABT492 and levofloxacin with Streptococcus pneumoniae in an in vitro dynamic model.
    Firsov AA; Alferova IV; Smirnova MV; Lubenko IY; Portnoy YA; Zinner SH
    Int J Antimicrob Agents; 2005 May; 25(5):409-13. PubMed ID: 15848296
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.